Stock of Interest (NWBO): Potentially Lose $0.5 or Gain $30 or More in Near Future

GlobeCitizen

新手上路
注册
2012-07-14
消息
120
点数
28
While we are waiting for the topline data to be released "soon," relax and listen to the US Democratic presidential candidate Andrew Yang's interview with former Obama presidential campaign manager David Axelrod, which is a very inspirational and information rich podcast about Andrew and his campaign. Andrew has made history for all the Asians living in the US, and Canada as well in a not so direct manner, and of course in the US history. Regardless how far he can go in the future, he has become a model for all as a kind, caring, problem-solving, and forward looking thinker. so enjoy!
https://luminarypodcasts.com/listen/the-institute-of-politics-and-david-axelrod-124/the-axe-files-with-david-axelrod-284/ep-359-andrew-yang/a54d79e7-d745-432d-a8d1-26cb49d791fd
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
120
点数
28
The long years of never-ending waiting and suffering manifested with this pure beauty of Tchaikovsky's Andante:

And maybe finally we are approaching the end of trial and also the beginning of prosperity embodied in this piece of beauty of Sarasate's Zigeunerweisen, full of melancholy and HOPE :
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
120
点数
28
Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management TeamPress Release | 12/12/2019
Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team
Executive With Decades of Public and Private Company Experience Joins NW Bio As CFO
PR Newswire

BETHESDA, Md., Dec. 12, 2019

BETHESDA, Md., Dec. 12, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has further expanded its senior management team with the addition of Ms. Jean M. Davis as Chief Financial Officer, Chief Accounting Officer, and interim Chief Information Officer.



Ms. Davis comes to NW Bio from BDO USA LLP, where she was a Risk Advisory Senior Manager. She is a Certified Public Accountant, Certified Sarbanes-Oxley Expert, Certified Internal Auditor, and Certified Project Management Professional. She obtained her Master of Science in Business with a concentration in Finance and Accounting from Johns Hopkins University.

Ms. Davis brings over 24 years of experience assisting both national and multi-national, public and private companies with their finance and accounting functions, financial reporting, compliance with financial, industry-specific and federal regulations, and related matters. Ms. Davis also worked previously at Deloitte & Touche.

"We are delighted to welcome Ms. Davis to NW Bio," commented NW Bio's CEO, Linda Powers. "We believe that her breath of knowledge and experience in finance and accounting, project management, data analytics and information technology, as well as her passion for our cause with DCVax®, will make Ms. Davis a strong addition to the NW Bio executive team."

Ms. Davis commented: "NW Bio is pursuing an exciting cause with its novel DCVax® immune therapies for cancer. I look forward to bringing my background and experience to bear to help take the Company to the next level.

About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
120
点数
28
顶部